Effect of Vaginal Progesterone and Dydrogesterone on Pregnancy Outcomes in patients with Threatened Abortion: A Randomized Clinical Trial

Document Type : Original Article

Authors

1 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. Kowsar Hospital Clinical Research Development Support Unit, Qazvin University of Medical Sciences, Qazvin, Iran

2 General Physician, Medical student Research Committee, Shahed University, Tehran, Iran.

3 Gynecologist and Obstetrician, Kosar Hospital, Qazvin University of Medical Sciences, Qazvin, Iran.

Abstract

Introduction: Despite the positive evidence on the effect of progesterone on protection of pregnancy in patients with threatened abortion, the results of studies regarding its drug type have been controversial. This study was performed with aim to compare the effect of vaginal progesterone and dydrogesterone on pregnancy outcome in cases with threatened abortion.
Methods: In this single-blind randomized clinical trial, 160 pregnant women with threatened abortion who referred to Qazvin Kowsar Hospital in 2018 were randomly assigned to receive dydrogesterone (Duphaston) 10 mg twice daily or vaginal progesterone (Cyclogest) 400 mg daily. Finally, pregnancy outcomes were compared between the two groups. Data were analyzed by SPSS software (version 18) and Chi-square, independent t-test and Mann-Whitney tests. P<0.05 was considered statistically significant.
Results: Frequency of cesarean section was 27 (33.7%) in the dydrogesterone group and 25 (31.2%) in the vaginal progesterone group (P = 0.736). In general, the incidence of preterm labor was 97 (60.6%) and there was no significant difference between the two groups (P >0.05). In addition, incidence of preeclampsia, gestational diabetes mellitus, placenta previa and intrauterine fetal death as well as neonatal weight were not significantly different between the two groups (P >0.05). Finally, maternal and neonatal complications showed no significant difference between the two groups (P = 0.675).
Conclusion: Pregnancy outcomes after administration of dydrogesterone are not different with vaginal progesterone in the treatment of threatened abortion.

Keywords

References

  1. Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. BioMed research international 2017; 2017.
  2. Moghadas Inanloo E, Keshavarz Z, Naeiji Z, Asgari M. Comparison of serum vitamin D levels in threatened abortion patients and women with normal pregnancy. Iran J Obstet Gynecol Infertil 2019; 22(10):49-57.
  3. Feodor Nilsson S, Andersen PK, Strandberg‐Larsen K, Nybo Andersen AM. Risk factors for miscarriage from a prevention perspective: a nationwide follow‐up study. BJOG 2014; 121(11):1375-85.
  4. Pakniat H, Bahman A, Ansari I. The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study. The Journal of Obstetrics and Gynecology of India 2019; 69(5):412-9.
  5. Zane S, Creanga AA, Berg CJ, Pazol K, Suchdev DB, Jamieson DJ, et al. Abortion-related mortality in the United States 1998–2010. Obstetrics and gynecology 2015; 126(2):258-65.
  6. Kanmaz AG, Inan AH, Beyan E, Budak A. The effects of threatened abortions on pregnancy outcomes. Ginekologia Polska 2019; 90(4):195-200.
  7. Saraswat L, Bhattacharya S, Maheshwari A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. BJOG 2010; 117(3):245-57.
  8. Ozdemirci S, Karahanoglu E, Esinler D, Gelisen O, Kayıkcıoglu F. Influence of threatened miscarriage on pregnancy and early postpartum period: a case–control report. The Journal of Maternal-Fetal & Neonatal Medicine 2015; 28(10):1186-9.
  9. Cho GJ, Choi SJ, Lee KM, Han SW, Kim HY, Ahn KH, et al. Women with threatened preterm labour followed by term delivery have an increased risk of spontaneous preterm birth in subsequent pregnancies: a population‐based cohort study. BJOG 2019; 126(7):901-5.
  10. Zhu CS, Tan TC, Chen HY, Malhotra R, Allen JC, Østbye T. Threatened miscarriage and depressive and anxiety symptoms among women and partners in early pregnancy. Journal of affective disorders 2018; 237:1-9.
  11. Hendriks E, MacNaughton H, MacKenzie MC. First trimester bleeding: evaluation and management. American Family Physician 2019; 99(3):166-74.
  12. Lotfalizadeh M, Khademi Z, Maleki A, Najaf Najafi M. Comparison of the duration of pregnancy in administration of progesterone suppository and Duphaston tablet in pregnant women with preterm labor after stopping delivery process. . Iran J Obstet Gynecol Infertil 2019; 22(10):1-11.
  13. Wang XX, Luo Q, Bai WP. Efficacy of progesterone on threatened miscarriage: Difference in drug types. Journal of Obstetrics and Gynaecology Research 2019; 45(4):794-802.
  14. Beigi A, Esmailzadeh A, Pirjani R. Comparison of risk of preterm labor between vaginal progesterone and17-alpha-hydroxy-progesterone Caproate in women with threatened abortion: A randomized clinical trial. International journal of fertility & sterility 2016; 10(2):162-68.
  15. Carp HJ. Progestogens in the prevention of miscarriage. Hormone Molecular Biology and Clinical Investigation 2016; 27(2):55-62.
  16. Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. Journal of reproduction & infertility 2014; 15(3):147-51.
  17. Al Mohamady M, Fattah GA, Elkattan E, Bayoumy R, Hamed DA. Correlation of serum CA-125 and progesterone levels with ultrasound markers in the prediction of pregnancy outcome in threatened miscarriage. International Journal of Fertility & Sterility 2016; 9(4):506-11.
  18. Lek SM, Ku CW, Allen Jr JC, Malhotra R, Tan NS, Østbye T, et al. Validation of serum progesterone< 35nmol/L as a predictor of miscarriage among women with threatened miscarriage. BMC Pregnancy and Childbirth 2017; 17(1):78.
  19. El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas 2009; 65:S43-6.
  20. Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertility and sterility 2014; 102(5):1357-63.
  21. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecological Endocrinology 2012; 28(12):983-90.
  22. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009; 65:S47-50.
  23. Palagiano A, Bulletti C, Pace MC, De Ziegler D, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Annals of the New York Academy of Sciences 2004; 1034(1):200-10.
  24. Alimohamadi S, Javadian P, Gharedaghi MH, Javadian N, Alinia H, Khazardoust S, et al. Progesterone and threatened abortion: a randomized clinical trial on endocervical cytokine concentrations. Journal of reproductive immunology 2013; 98(1-2):52-60.
  25. Raghupathy R, Al‐Azemi M. Modulation of cytokine production by the dydrogesterone metabolite dihydrodydrogesterone. American Journal of Reproductive Immunology 2015; 74(5):419-26.
  26. Khosravi D, Taheripanah R, Taheripanah A, Monfared VT, Hosseini-Zijoud SM. Comparison of oral dydrogesterone with vaginal progesteronefor luteal support in IUI cycles: a randomized clinical trial. Iran J Reprod Med 2015; 13(7):433-38.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 24, Issue 1
March 2021
Pages 18-25

Files

Share

How to cite

Statistics